anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the subject promoter optimal in application as a percutaneous agent in order to improve its migration into the skin with esp. no side effects as a therapeutic agent for alopecia such as alopecia areata and baldness, containing a protein kinase inhibitor as active ingredient. CONSTITUTION:The objective trichogenous promoter containing, as active ingredient, a protein kinase inhibitor of formula I (R1 is H or 2 to 3C alkylene chain in combination with R3; R2 is H, lower alkyl, amidino, aryl, etc.; R3 is H or the same mentioned above, and the heterocycle formed in the latter case may be substituted by 1 to 2 lower alkyls; R4 is H or halogen; X is C or N; (n) is 2 or 3). When to be used, the present promoter is made into a formulation in the form of lotion or cream. The concentration of the active ingredient in the formulation is 0.001 to 10wt.% depending on its use.
In 2004, then Surgeon General Carmona stated that a health literate individual is more apt to know the answer, when asked how to keep themselves well (AHRQ, 2004). There is a burgeoning movement among medical professionals to address health literacy. Teaching health information to children will empower them to actively participate in their current care and provide self-management skills that will assist them to keep themselves well throughout their lives. Currently, few medication administration instructional cards exist that are appropriate for children. Providing medication information that the child might understand may result in better administration compliance, fewer adverse effects and develop an individual that is knowledgeable regarding medications and appropriate administration. The purpose if this research is to develop medication administration cards, appropriate for children, which provide information on the most commonly used drugs among the Hematology/Oncology population.

The overall objective of this research is to develop medication informational cards for medications frequently used within the Hematology/Oncology pediatric population, and evaluate the effectiveness of these cards, by means of a pre- and post-test.
We will study two groups of 198 people with hypertension treated in ten health care units. One group will receive usual care dispensed in units (control). The other group (intervention) will be offered six individual assistance with health care worker physician or nurse) during the period of 9 months with a minimum interval of 30 days, plus 9 monthly visits structured by community health agents. Adherence will be measured in both groups at baseline and months 3, 6, 9 and 12, through validated questionnaire and pill count. Also evaluated clinical outcome measures (blood pressure, hospitalizations and deaths). The analysis will be done by intention to treat comparing adherence measures and clinical outcome between groups (Student t test and chi-square test) and within groups over time (paired t test and McNemar). It will be accepted p value \<0.05.
663. Matthews, F. E., and Strange, E. H. Jan. 9. Liniments, embrocations, ointments, and salves.-Pharmaceutical preparations for external application contain salicylic esters of isopropyl or butyl alcohols or of poly - hydric alcohols, together with solvents, oils, fats, waxes, or anointing preparations, or with solid or semi-solid materials to form a paste. Antiseptics such as cresol may also be added. The esters mentioned are those of iso-propyl and normal butyl alcohol and of the glycols and glycerols. The additional substances mentioned are petroleum jelly, paraffin wax, wool fat or lanoline, carron oil (olive or linseed oil with lime water), linseed oil, iso-amyl salicylate, zinc oxide, magnesium carbonate, and precipitated chalk.
Carcinogenicity studies have not been conducted with axitinib.

Axitinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not clastogenic in the in vitro human lymphocyte chromosome aberration assay. Axitinib was genotoxic in the in vivo mouse bone marrow micronucleus assay.

INLYTA has the potential to impair reproductive function and fertility in humans. In repeat-dose toxicology studies, findings in the male reproductive tract were observed in the testes/epididymis (decreased organ weight, atrophy or degeneration, decreased numbers of germinal cells, hypospermia or abnormal sperm forms, reduced sperm density and count) at ≥15 mg/kg/dose administered orally twice daily in mice (approximately 7 times the systemic exposure (AUC) in patients at the recommended starting dose) and ≥1.5 mg/kg/dose administered orally twice daily in dogs (approximately 0.1 times the AUC in patients at the recommended starting dose). Findings in the female reproductive tract in mice and dogs included signs of delayed sexual maturity, reduced or absent corpora lutea, decreased uterine weights and uterine atrophy at ≥5 mg/kg/dose (approximately 1.5 or 0.3 times the AUC in patients at the recommended starting dose compared to mice and dogs, respectively).

In a fertility study in mice, axitinib did not affect mating or fertility rate when administered orally twice daily to males at any dose tested up to 50 mg/kg/dose following at least 70 days of administration (approximately 57 times the AUC in patients at the recommended starting dose). In female mice, reduced fertility and embryonic viability were observed at all doses tested (≥15 mg/kg/dose administered orally twice daily) following at least 15 days of treatment with axitinib (approximately 10 times the AUC in patients at the recommended starting dose).
BACKGROUND: Surgical resection is the primary treatment for bone and soft tissue tumors. Negative margin status is a key factor in prognosis. Given the three-dimensional (3D) anatomic complexity of musculoskeletal tumor specimens, communication of margin results between surgeons and pathologists is challenging. We sought to perform ex vivo 3D scanning of musculoskeletal oncology specimens to enhance communication between surgeons and pathologists.
METHODS: Immediately after surgical resection, 3D scanning of the fresh specimen is performed prior to frozen section analysis. During pathologic grossing, whether frozen or permanent, margin sampling sites are annotated on the virtual 3D model using computer-aided design (CAD) software.
RESULTS: 3D scanning was performed in seven cases (six soft tissue, one bone), with specimen mapping on six cases. Intraoperative 3D scanning and mapping was performed in one case in which the location of margin sampling was shown virtually in real-time to the operating surgeon to help achieve a negative margin. In six cases, the 3D model was used to communicate final permanent section analysis. Soft tissue, cartilage, and bone (including lytic lesions within bone) showed acceptable resolution.
CONCLUSIONS: Virtual 3D scanning and specimen mapping is feasible and may allow for enhanced documentation and communication. This protocol provides useful information for anatomically complex musculoskeletal tumor specimens. Future studies will evaluate the effect of the protocol on positive margin rates, likelihood that a re-resection contains additional malignancy, and exploration of targeted adjuvant radiation protocols using a patient-specific 3D specimen map.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic capable of improving the physiological activities of skin tissues and skin cells and recovering the original physiological functions of the skin, thereby capable of enhancing the moisture retainability of the skin to make the fresh and youthful skin. SOLUTION: An extracted ingredient obtained by immersing Borago officinalis L. (belonging to the genus BORAGO in the family Boraginaceae) in a solvent is added to a skin cosmetic (e.g. skin lotion, lotion, milky lotion, cream, pack, etc.,). The solvent includes water, ethanol and 1,3-butyleneglycol. A remarkable moisture-retaining effect is obtained in comparison with conventional moisturizing agents (e.g. glycerol).
This will be a single-center, prospective, randomized controlled trial. A report of patients who use the Vanderbilt Specialty Pharmacy (VSP) will be generated daily for patients with a proportion of days covered (PDC) \< 90% in the previous 4 and 12 months based on pharmacy claims. Patients who meet criteria will be randomized to receive an intervention corresponding to their specific reason for nonadherence and follow up from a specialty pharmacist or to receive usual care. For patients who are randomized to receive an intervention, the specialty pharmacist will review their medication fill history and electronic health record to identify potential reasons for nonadherence or to see if the pharmacy claims inappropriately categorized them as nonadherent (this could be due to holding treatment for a clinical reason, transferring the prescription outside of VSP or other reasons listed in Table 2). After reviewing the patient's pharmacy and medical history, if the pharmacist believes they are truly nonadherent (not taking medication as prescribed), the patient will be contacted to identify potential reasons for nonadherence and intervention(s) will be provided to combat the identified reasons for nonadherence. Adherence rates for those receiving the additional adherence interventions and those receiving standard of care will be calculated 8 months after the date of randomization. The reasons for nonadherence and the intervention to improve adherence rates will be documented in a secured REDCap database. It is important to note that the adherence pharmacist is not study staff, but a full-time employee of the health-system specialty pharmacy performing normal specialty pharmacist functions. The randomization to receive these services or not will allow for evaluation of their efficacy.
Subjects will be recruited from three regions in Panama known to be endemic for L panamensis CL. Subjects will be screened over a period up to 28 days for eligibility including medical history, physical examination, leishmaniasis history, vital signs, clinical chemistry, prior medications, and parasitology for confirmation of ulcerative CL. If eligible, subjects will be randomized in a targeted 1:1 ratio (200 subjects per group) using site as a stratification variable to receive either WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) or Paromomycin Alone (15% paromomycin topical cream) by topical application to CL lesions once daily for 20 days. Efficacy will be assessed by measuring the size of the index lesion ulcer, non-index lesions ulcers, and overall size of other non-ulcerated lesions at baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days. A notation will be made if clinical evidence of parasite persistence is observed at the Day 63 and beyond visits including significant erythema and induration when a lesion has otherwise completely re-epithelialized to document any subjects removed from the study early if the investigator judges them to be in need of rescue treatment. A photograph will be taken of all lesions at baseline, Day 20 and each of the follow-up visits. Safety will be assessed by monitoring adverse events (AEs) from the start of treatment until study completion, lesion site reactions during treatment, physical examination of the nasal and oral mucosa for appearance of mucosal leishmaniasis on Days 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days, concomitant medication use for the duration of the study, blood creatinine, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels on Study Day 20. After the sponsor's approval, biochemistry can be repeated in the case of abnormal results and if the causes of these results could not be determined. A repeat pregnancy test on Day 35. Recent infection with leishmaniasis prior to the start of the study may result in the development of lesions that were not present at the start of the study that did not receive treatment. New lesions may be treated at the discretion of the investigator with the topical cream to which the subject was assigned any time during the conduct of the study except that treatment must be completed by the Day 168 visit. If a new lesion is discovered at the final study visit, the subject will be referred to their primary physician for treatment.

Subjects who fail therapy (see definition of failure below) will be taken off study and may be administered rescue therapy at the discretion of the subject's personal physician. If the subject met the criteria for therapy failure but was undergoing treatment for new lesions, the subject can continue in the study (by signing a consent addendum) if the investigator decides it is in the best interest of the subject to do so.
The use of campylobacter jejuni and its toxins in the manufacture of a medicament for the prevention, diagnosis, prognosis, treatment of colorectal cancer and parenteral tumour metastasis. Campylobacter, particularly campylobacter jejuni, and toxin CDT can be used as a marker to distinguish whether metastasis has occurred in colorectal cancer patients. Experiments prove that the campylobacter jejuni promotes the metastasis and invasion capacity, the campylobacter jejuni promotes the invasion and metastasis of colon cancer cells through the CDT protein and the JAK2/STAT3/MMP9 signal pathway in tumor cells activated and upregulated by the campylobacter jejuni, and the tumor metastasis promotion capacity of the campylobacter jejuni is weakened or disabled when the process is blocked. Campylobacter jejuni also promotes metastasis of extra-intestinal tumors. Based on drugs or agents which block this process, for the prevention, inhibition of metastasis of colorectal cancer cells and extra-intestinal tumors, and based on campylobacter jejuni and its toxins, corresponding agents or methods were developed for the diagnosis or prognosis of metastasis of colorectal cancer and extra-intestinal tumors. The marker provided by the application is expected to inhibit tumor metastasis and prolong the survival time of patients.
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate several cardiovascular and respiratory diseases. Sarcoidosis is a multisystemic disorder that is characterized by non-caseating granulomas which are present in multiple tissues, particularly in the lung and lymphatic system. Severe untreated pulmonary hypertension (PH) carries a poor prognosis and is associated with higher mortality in participants with interstitial lung diseases and sarcoidosis. While there is no approved treatment for SAPH, PH-specific treatments are frequently used. Selexipag is a selective, orally available and long-acting non-prostanoid agonist of the prostacyclin receptor (prostacyclin \[IP\] receptor) for the treatment of patients with PAH. The rationale for this study is based on the unmet medical need for new therapeutic options for patients with SAPH and is supported by the established efficacy and safety of selexipag in the PAH indication, the shared pathomechanism between SAPH and PAH, and the available data on the efficacy and safety of PH-specific therapies in SAPH. This study consists of screening period, main observation period and double blind extension period and safety follow-up period. The duration of individual participation in the study will be different for each individual participant (between approximately 15 months and up to approximately 3.5 years) and will depend on the time of each participant's individual date of entering the study and the total recruitment time. The efficacy assessments include right heart catheterization (RHC), assessment of exercise capacity, dyspnea, pulmonary function tests, etc. Safety and tolerability will be evaluated throughout the study and includes review of concomitant medications and adverse events (AEs), clinical laboratory tests, 12-lead electrocardiogram (ECG), vital signs, physical examination, and pregnancy testing.
Participants first receive 125 mg of MDMA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
A randomized, evaluator-blinded, within subject (split face) multicenter clinical study of DA-13-007 (Injectable poly-l-lactic acid) compared to SCULPTRA in the treatment of nasolabial fold wrinkles. Qualifying subjects will be randomized to receive DA-13-007 and SCULPTRA on either the right or left side of the face. The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed. The follow-up phase will consist of assessments at 1, 3, 6, and 12 months after the last treatment, and safety and efficacy evaluations for an additional 12 months. Standardized photographs will be taken at screening and at all treatment phase and follow-up visits. Efficacy evaluations will be made by an on-site blinded evaluator, and of the photographs using a validated, standardized photo-numeric scale. The primary efficacy comparison between study treatments will be made on the mean change from baseline in the Wrinkle Severity Rating Scale of the nasolabial folds (as determined by the on-site blinded evaluator) and at the 12 month time point. Study participants will continue to be followed for safety and efficacy at months 18 and 24 after their last injection session.
To provide porous silica particles used in a general-purpose bioactive substance carrier.SOLUTION: Provided is a porous silica particles having a plurality of pores with a diameter of 5 nm to 100 nm and having t of not less than 24, at which a ratio of absorbance measured by numerical expression At/A0 is 1/2. In the above numerical expression, A0 denotes an absorbance of the porous silica particle measured after putting 5 ml of a suspension including 1 mg/ml of the porous silica particle in a cylindrical permeable membrane having pores with a diameter of 50 kDa. On the outside of the permeable membrane, 15 ml of a solvent in contact with the permeable membrane and substantially identical to the suspension is present. The inner and outer portions of the permeable membrane are horizontally agitated at 37°C and 60 rpm. The suspension has pH 7.4. At denotes an absorbance of the porous silica particles measured t hour after the measurement of A0.SELECTED DRAWING: Figure 8
BACKGROUND & AIMS: Treatments directly targeting fibrosis remain limited. Given the unique intrinsic features of macrophages and their capacity to engraft in the liver, we genetically engineered bone marrow-derived macrophages with a chimeric antigen receptor (CAR) to direct their phagocytic activity against hepatic stellate cells (HSCs) in multiple mouse models. This study aimed to demonstrate the therapeutic efficacy of CAR macrophages (CAR-Ms) in mouse models of fibrosis and cirrhosis and to elucidate the underlying mechanisms.
METHODS: uPAR expression was studied in patients with fibrosis/cirrhosis and in murine models of liver fibrosis, including mice treated with carbon tetrachloride, a 5-diethoxycarbonyl-1, 4-dihydrocollidine diet, or a high-fat/cholesterol/fructose diet. The safety and efficacy of CAR-Ms were evaluated in vitro and in vivo.
RESULTS: Adoptive transfer of CAR-Ms resulted in a significant reduction in liver fibrosis and the restoration of function in murine models of liver fibrosis. CAR-Ms modulated the hepatic immune microenvironment to recruit and modify the activation of endogenous immune cells to drive fibrosis regression. These CAR-Ms were able to recruit and present antigens to T cells and mount specific antifibrotic T-cell responses to reduce fibroblasts and liver fibrosis in mice.
CONCLUSION: Collectively, our findings demonstrate the potential of using macrophages as a platform for CAR technology to provide an effective treatment option for liver fibrosis. CAR-Ms might be developed for treatment of patients with liver fibrosis.
IMPACT AND IMPLICATIONS: Liver fibrosis is an incurable condition that afflicts millions of people globally. Despite the clear clinical need, therapies for liver fibrosis are limited. Our findings provide the first preclinical evidence that chimeric antigen receptor (CAR)-macrophages (CAR-Ms) targeting uPAR can attenuate liver fibrosis and cirrhosis. We show that macrophages expressing this uPAR CAR exert a direct antifibrotic effect and elicit a specific T-cell response that augments the immune response against liver fibrosis. These findings demonstrate the potential of using CAR-Ms as an effective cell-based therapy for the treatment of liver fibrosis.
The present invention discloses a preparation method of icodextrin for a starch-based peritoneal dialysis solution. According to the technical scheme of the invention, native starch is adopted as a raw material, and then a starch solution with the concentration thereof to be 5% to 15% is prepared by using a phosphate buffered solution. At a certain temperature and a certain pH value, the starch solution is firstly subjected to enzymolysis by using alpha-amylase, and then the gelatinized starch is subjected to debranching by using a debranching enzyme. The enzymatic hydrolysate is subjected to alcohol precipitation, ultrafiltration, gel chromatographic column separation and purification, and then the weight-average and number-average molecular weights thereof and the alpha-1, 6 glycosidic bond thereof meet the requirements at the same time. The content of alpha-1, 6 glycosidic bond in icodextrin is smaller than 10%, and the weight-average molecular weight thereof is 13000 to 19000 Da. The number-average molecular weight thereof is 5000 to 6500 Da. The preparation method of icodextrin for the starch-based peritoneal dialysis solution is high in yield, good in quality and relatively low in cost. Meanwhile, the defects of the conventional icodextrin preparation process in the prior art are overcome.
Palifermin was not carcinogenic in a 26-week study in rasH2 transgenic mice at intravenous doses of 0.1, 1, or 10 mg/kg/dose. 

Palifermin was not genotoxic in the reverse mutation bacterial (Ames) test, cytogenic test, or rat micronucleus assay. 

In a fertility and early embryonic development study, palifermin was administered intravenously to male and female rats at doses of 100, 300 or 1000 μg/kg/day. Males were dosed 28 days prior to mating through cohabitation and females were dosed 14 days prior to mating through gestation Day 7. Decreased epididymal sperm counts, and increased post-implantation losses were observed at doses ≥ 300 μg/kg/day (5 fold the recommended human dose, on a body weight basis). Increased pre-implantation loss and decreased fertility index, were observed at a palifermin dose of 1000 μg/kg/day.
FIELD: medical industry, in particular, methods of production of emulsions that can carry oxygen and are intended for use as blood substitutes, media for preservation of isolated organs, and as radiopaque agents. SUBSTANCE: the method enhances the monodispersity of emulsion due to the decrease of particles measuring more than 0.2 mcm in it. The mixture of perfluoro-carbon compounds and emulsifying agent is passed alternately through the main and additional circulation circuits of the homogenizer. Preemulsion is obtained in the main circulation circuit by dropping the above mixture of through the vessel with emulsifying agent and by pumping the obtained mixture through the homogenizer. The mixture is taken in relation 2:1, and only proxanol is used as emulsifying agent. The method provides for production of highly stable fully submicrometric emulsions with an average size of particles within 0.06 to 0.11 mcm, and the share of particles measuring more than 0.2 mcm makes up 0.4%. The emulsion can be stored at t=+20 C up to a month without worsening of its quality, there is no need to sterilize the emulsion after its production. EFFECT: simplified technology and improved conditions of process sterility. 2 cl, 1 dwg, 9 tbl